메디쎄이 Stock: price and insider trades · South Korea

This page follows insider dealings at 메디쎄이 as filed with DART (FSS), a company from the Health Care sector. 2 insiders have disclosed 4 filings since 2 November 2025.

Not one open-market sale was filed. On the buying side, 2 insiders reported 4 purchases totalling €237k. The totals exclude 3 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €237k, the purchase published on 27 March 2026 by 동화약품 is the largest of the period. Those buying include 1 chief executive.

The last purchase on record was published on 29 September 2026, which is 42 days ago.

For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 4 filings here. Our records for 메디쎄이 go back to 2022, with 6 purchases and no sales on the open market in total.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.